Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    18809924 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Conditions: Leber Congenital Amaurosis (LCA);   Eye Diseases;   Eye Diseases, Hereditary;   Retinal Diseases
Intervention: Genetic: AAV2/5-OPTIRPE65
2 Recruiting Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Condition: Leber Congenital Amaurosis
Intervention: Genetic: rAAV2-hRPE65
3 Active, not recruiting Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
Conditions: Amaurosis of Leber;   Retinal Diseases
Intervention: Genetic: rAAV2-CBSB-hRPE65

Indicates status has not been verified in more than two years